Literature DB >> 36241849

Scaffolds: a biomaterial engineering in targeted drug delivery for osteoporosis.

Safoora Poorirani1, Sayed Latif Taheri1, Sayed Abolfazl Mostafavi2.   

Abstract

Osteoporosis is an increasingly common condition that causes low bone density, porous bone, and increased fracture risk. Treatments for osteoporosis are divided into two categories: (a) antiresorptive and (b) anabolic. To decrease side effects of drug and dosage level variations caused by several consecutive administrations, various drug delivery systems have been proposed. Among them, scaffolds are one of the drug delivery systems that led to drug impart with high loading and suitable efficiency to specific sites which retain active agents at acceptable therapeutic levels. The purpose of this review was to explain the role of scaffolds in targeted drug delivery to bone tissue for the treatment of osteoporosis.
© 2022. International Osteoporosis Foundation and Bone Health and Osteoporosis Foundation.

Entities:  

Keywords:  Biomaterial engineering; Drug delivery; Osteoporosis; Scaffold; Targeted

Year:  2022        PMID： 36241849     DOI： 10.1007/s00198-022-06543-3

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   5.071


  40 in total

Review 1.  Biomechanical and molecular regulation of bone remodeling.

Authors:  Alexander G Robling; Alesha B Castillo; Charles H Turner
Journal:  Annu Rev Biomed Eng       Date:  2006       Impact factor: 9.590

2.  Statins and osteoporosis: a latent promise.

Authors:  Elda Leonor Pacheco-Pantoja; Jose Alvarez-Nemegyei
Journal:  Reumatol Clin       Date:  2014-06-02

3.  Postmenopausal Osteoporosis.

Authors:  Karl Michaëlsson; Per Aspenberg
Journal:  N Engl J Med       Date:  2016-05-26       Impact factor: 91.245

4.  Raloxifene microsphere-embedded collagen/chitosan/β-tricalcium phosphate scaffold for effective bone tissue engineering.

Authors:  Ming-Lei Zhang; Ji Cheng; Ye-Chen Xiao; Ruo-Feng Yin; Xu Feng
Journal:  Int J Pharm       Date:  2016-12-14       Impact factor: 5.875

Review 5.  How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis.

Authors:  P J Marie; D Felsenberg; M L Brandi
Journal:  Osteoporos Int       Date:  2010-09-02       Impact factor: 4.507

6.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY.

Authors:  Pauline M Camacho; Steven M Petak; Neil Binkley; Bart L Clarke; Steven T Harris; Daniel L Hurley; Michael Kleerekoper; E Michael Lewiecki; Paul D Miller; Harmeet S Narula; Rachel Pessah-Pollack; Vin Tangpricha; Sunil J Wimalawansa; Nelson B Watts
Journal:  Endocr Pract       Date:  2016-09       Impact factor: 3.443

7.  BMP-2 induced early bone formation in spine fusion using rat ovariectomy osteoporosis model.

Authors:  Sung Bae Park; Seong Hoon Park; Na-Hyung Kim; Chun Kee Chung
Journal:  Spine J       Date:  2013-08-13       Impact factor: 4.166

Review 8.  Denosumab in osteoporosis.

Authors:  Dima L Diab; Nelson B Watts
Journal:  Expert Opin Drug Saf       Date:  2013-12-02       Impact factor: 4.250

Review 9.  Teriparatide: a review of its use in osteoporosis.

Authors:  Stephanie K A Blick; Sohita Dhillon; Susan J Keam
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 10.  Gallium containing bioactive materials: A review of anticancer, antibacterial, and osteogenic properties.

Authors:  Fatih Kurtuldu; Nurshen Mutlu; Aldo R Boccaccini; Dušan Galusek
Journal:  Bioact Mater       Date:  2022-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.